Close Menu

This article has been updated to include comments from NeoGenomics' earnings call.

NEW YORK (GenomeWeb) – NeoGenomics today reported year over year growth of 159 percent in its second quarter revenues driven by an increase in clinical genetic testing volume. 

For the three-month period ended June 30, the company posted revenues of $63.1 million compared with $24.4 million a year earlier.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.